Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: Is the synergy worth the risk?

Stephen B. Hanauer

doi:10.1136/gut.2006.115980

Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: Is the synergy worth the risk?

Stephen B. Hanauer^*

^*Corresponding author for this work

Medicine, Gastroenterology Division

Research output: Contribution to journal › Review article › peer-review

43 Scopus citations

Abstract

Since the introduction of infliximab to treat Crohn's disease, combination therapy with immunosuppressants has reduced immunogenicify, without impacting efficacy. The availability of novel anti-TNF agents and potential combined toxicities question the risk/benefit of combination therapies.

Original language	English (US)
Pages (from-to)	1181-1183
Number of pages	3
Journal	Gut
Volume	56
Issue number	9
DOIs	https://doi.org/10.1136/gut.2006.115980
State	Published - Sep 2007

ASJC Scopus subject areas

Gastroenterology

Access to Document

10.1136/gut.2006.115980

Cite this

@article{526b1e46df814c1081bc6a6f1584a368,

title = "Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: Is the synergy worth the risk?",

abstract = "Since the introduction of infliximab to treat Crohn's disease, combination therapy with immunosuppressants has reduced immunogenicify, without impacting efficacy. The availability of novel anti-TNF agents and potential combined toxicities question the risk/benefit of combination therapies.",

author = "Hanauer, {Stephen B.}",

year = "2007",

month = sep,

doi = "10.1136/gut.2006.115980",

language = "English (US)",

volume = "56",

pages = "1181--1183",

journal = "Gut",

issn = "0017-5749",

publisher = "BMJ Publishing Group",

number = "9",

}

TY - JOUR

T1 - Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease

T2 - Is the synergy worth the risk?

AU - Hanauer, Stephen B.

PY - 2007/9

Y1 - 2007/9

N2 - Since the introduction of infliximab to treat Crohn's disease, combination therapy with immunosuppressants has reduced immunogenicify, without impacting efficacy. The availability of novel anti-TNF agents and potential combined toxicities question the risk/benefit of combination therapies.

AB - Since the introduction of infliximab to treat Crohn's disease, combination therapy with immunosuppressants has reduced immunogenicify, without impacting efficacy. The availability of novel anti-TNF agents and potential combined toxicities question the risk/benefit of combination therapies.

UR - http://www.scopus.com/inward/record.url?scp=34548118412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548118412&partnerID=8YFLogxK

U2 - 10.1136/gut.2006.115980

DO - 10.1136/gut.2006.115980

M3 - Review article

C2 - 17698862

AN - SCOPUS:34548118412

SN - 0017-5749

VL - 56

SP - 1181

EP - 1183

JO - Gut

JF - Gut

IS - 9

ER -

Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: Is the synergy worth the risk?

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this